Logo image of BGM

BGM GROUP LTD (BGM) Stock Fundamental Analysis

USA - NASDAQ:BGM - KYG7307E1237 - Common Stock

9.4 USD
-0.12 (-1.26%)
Last: 10/22/2025, 8:17:36 PM
9.31 USD
-0.09 (-0.96%)
After Hours: 10/15/2025, 8:15:51 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to BGM. BGM was compared to 191 industry peers in the Pharmaceuticals industry. BGM scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. BGM has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

BGM had negative earnings in the past year.
In the past year BGM has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: BGM reported negative net income in multiple years.
In the past 5 years BGM always reported a positive cash flow from operatings.
BGM Yearly Net Income VS EBIT VS OCF VS FCFBGM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M

1.2 Ratios

Looking at the Return On Assets, with a value of -1.31%, BGM is in the better half of the industry, outperforming 76.96% of the companies in the same industry.
BGM has a Return On Equity of -1.49%. This is amongst the best in the industry. BGM outperforms 80.63% of its industry peers.
Industry RankSector Rank
ROA -1.31%
ROE -1.49%
ROIC N/A
ROA(3y)-5.41%
ROA(5y)-0.31%
ROE(3y)-6.51%
ROE(5y)1.12%
ROIC(3y)N/A
ROIC(5y)N/A
BGM Yearly ROA, ROE, ROICBGM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 30

1.3 Margins

BGM's Gross Margin of 19.41% is in line compared to the rest of the industry. BGM outperforms 52.88% of its industry peers.
BGM's Gross Margin has declined in the last couple of years.
BGM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 19.41%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y18.4%
GM growth 5Y-4.83%
BGM Yearly Profit, Operating, Gross MarginsBGM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20

More info and screens

5

2. Health

2.1 Basic Checks

BGM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BGM has less shares outstanding
BGM has less shares outstanding than it did 5 years ago.
There is no outstanding debt for BGM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BGM Yearly Shares OutstandingBGM Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
BGM Yearly Total Debt VS Total AssetsBGM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

An Altman-Z score of 36.97 indicates that BGM is not in any danger for bankruptcy at the moment.
The Altman-Z score of BGM (36.97) is better than 96.86% of its industry peers.
BGM has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
BGM has a Debt to Equity ratio (0.01) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 36.97
ROIC/WACCN/A
WACC7.63%
BGM Yearly LT Debt VS Equity VS FCFBGM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M 30M 40M 50M

2.3 Liquidity

A Current Ratio of 1.82 indicates that BGM should not have too much problems paying its short term obligations.
BGM has a worse Current ratio (1.82) than 63.35% of its industry peers.
A Quick Ratio of 1.45 indicates that BGM should not have too much problems paying its short term obligations.
BGM has a worse Quick ratio (1.45) than 61.78% of its industry peers.
Industry RankSector Rank
Current Ratio 1.82
Quick Ratio 1.45
BGM Yearly Current Assets VS Current LiabilitesBGM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

0

3. Growth

3.1 Past

BGM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 74.40%, which is quite impressive.
The Revenue for BGM has decreased by -10.12% in the past year. This is quite bad
The Revenue for BGM have been decreasing by -11.45% on average. This is quite bad
EPS 1Y (TTM)74.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-146.9%
Revenue 1Y (TTM)-10.12%
Revenue growth 3Y-23.97%
Revenue growth 5Y-11.45%
Sales Q2Q%13.92%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BGM Yearly Revenue VS EstimatesBGM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BGM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BGM Price Earnings VS Forward Price EarningsBGM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BGM Per share dataBGM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BGM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BGM GROUP LTD

NASDAQ:BGM (10/22/2025, 8:17:36 PM)

After market: 9.31 -0.09 (-0.96%)

9.4

-0.12 (-1.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)07-24 2025-07-24
Earnings (Next)N/A N/A
Inst Owners0.09%
Inst Owner ChangeN/A
Ins Owners25.02%
Ins Owner ChangeN/A
Market Cap1.53B
Revenue(TTM)26.85M
Net Income(TTM)-2718500
AnalystsN/A
Price TargetN/A
Short Float %0.13%
Short Ratio1.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 56.88
P/FCF N/A
P/OCF N/A
P/B 8.39
P/tB 36.11
EV/EBITDA N/A
EPS(TTM)-0.28
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.04
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS0.17
BVpS1.12
TBVpS0.26
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -1.31%
ROE -1.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 19.41%
FCFM N/A
ROA(3y)-5.41%
ROA(5y)-0.31%
ROE(3y)-6.51%
ROE(5y)1.12%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y18.4%
GM growth 5Y-4.83%
F-Score3
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 151.04%
Cap/Sales 6.33%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.82
Quick Ratio 1.45
Altman-Z 36.97
F-Score3
WACC7.63%
ROIC/WACCN/A
Cap/Depr(3y)184.23%
Cap/Depr(5y)176.99%
Cap/Sales(3y)4.89%
Cap/Sales(5y)4.34%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)74.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-146.9%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-10.12%
Revenue growth 3Y-23.97%
Revenue growth 5Y-11.45%
Sales Q2Q%13.92%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y39.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-211.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-163.33%
OCF growth 3Y15.85%
OCF growth 5YN/A